N/A N=150 Miller Straight Blade vs Macintosh Blade
Intubation; Difficult
Primary: Ease of Intubation or Degree of Difficulty With Intubation — 52; 54; 23; 16 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=78 Recording for Potential AF Drivers and Patient Specific Atrial Anatomy & Atrial Electrogram Maps
Atrial Fibrillation
Primary: Percentage of Drivers in Right Atrial — 25.3 percentage of rotor sources
N/A N=40 Sirolimus Conversions in African-American Renal Transplant Recipients
Absence; Kidney
Primary: Effectiveness and Safety of a Particular Drug Regimen to Prevent Kidney Rejection — 4; 1 participants
N/A N=765 Observation of Patients With Metastatic Colorectal Cancer Starting Chemotherapy Combined With Bevacizumab (Avastin)
Metastatic Colorectal Cancer
Primary: Progression-free Survival — 10.4; 8.5; 6.3 Months
N/A N=27 1068GCC Evaluate Efficacy & Explore Mechanism of Acupuncture in Treating Bortezomib-induced Peripheral Neuropathy (BIPN) in Multiple Myeloma
Peripheral Neuropathies · Multiple Myeloma
Primary: To Determine the Response Rate (Via FACT/GOG-Ntx Scores) Effectiveness and Safety of Acupuncture in Alleviating Neuropathic Symptoms When Treating Patients With Moderate…
N/A N=12 Photocil (Topical) for the Treatment of Psoriasis Vulgaris
Psoriasis
Primary: Percent Lesion Clearance — 75.7; 8 Percent Clearance
Phase 1 N=22 Topical Myristyl Nicotinate Cream on the Skin of Healthy Volunteers
Healthy
Primary: Participants With Adverse Events by Treatment. — 8; 2 participants — p=0.01
Phase 1 N=31 Mouse Cancer Cell-containing Macrobeads in the Treatment of Human Cancer
Intraabdominal Cancers (Various Types)
Primary: Maximum Tolerated Dose (MTD) of RENCA Macrobeads — NA RENCA Macrobeads/kg
Phase 2 N=35 A Study Of Intravenous Sulopenem And Oral PF-03709270 In Community Acquired Pneumonia That Requires Hospitalization
Pneumonia, Bacterial
Primary: Percentage of Participants With Clinical Response at Test of Cure (TOC) Visit — 90.0; 87.5; 62.5; 10.0 percentage of participants
Phase 1 N=46 A Study to Assess Pharmacokinetics (PK) of Preladenant in Participants With Chronic Renal Impairment (CRI) (P06512)
Parkinson Disease
Primary: Area Under the Concentration-time Curve From Time 0 to Infinity (AUC0-∞) After Single Dosing With Preladenant for Participants With Severe CRI Versus Healthy Matched…
Phase 2 N=11 Dose Escalation Followed by Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast Cancer
Breast Cancer
Primary: Maximum Tolerated Dose (MTD) — 0; 0 participants with DLT
Phase 2 N=42 Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma
Adult Nasal Type Extranodal NK/T-Cell Lymphoma · Anaplastic Large Cell Lymphoma · Angioimmunoblastic T-Cell Lymphoma
Primary: Objective Response Rate (Complete Responses (CR) + Partial Responses (PR)) — 2; 7; 28 participants
Phase 2 N=19 Combined Transcranial Direct Current Stimulation and Motor Imagery-based Robotic Arm Training for Stroke Rehabilitation
Stroke
Primary: Upper Extremity Component of Fugl-Meyer Assessment — 35.3; 32.6; 0.9; 0.8 units on a scale
N/A N=195 Effects of Adding Motivational Interviewing to Antidepressant Treatment for Hispanic Adults With Depression
Depression
Primary: Number of Days in ADT (Retention) — 59.5; 65.5; 148.7; 164.1 Days in treatment — p=0.26
Phase 3 N=583 Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women
Acquired Immunodeficiency Syndrome · HIV Infections
Primary: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 of the Double-Blind Phase as Determined by the US FDA-Defined Snapshot Algorithm — 87.2; 80.8…